Terms: = Colorectal cancer AND PAM50
9 results:
1. The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis.
E Y; Xue H; Zhang CY; Zhao MZ; Zheng HC
Histol Histopathol; 2023 Apr; 38(4):453-465. PubMed ID: 36255176
[TBL] [Abstract] [Full Text] [Related]
2. classifieR a flexible interactive cloud-application for functional annotation of cancer transcriptomes.
Quinn GP; Sessler T; Ahmaderaghi B; Lambe S; VanSteenhouse H; Lawler M; Wappett M; Seligmann B; Longley DB; McDade SS
BMC Bioinformatics; 2022 Mar; 23(1):114. PubMed ID: 35361119
[TBL] [Abstract] [Full Text] [Related]
3. PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Fitzal F; Filipits M; Fesl C; Rudas M; Greil R; Balic M; Moinfar F; Herz W; Dubsky P; Bartsch R; Ferree S; Schaper C; Gnant M;
Br J Surg; 2021 Apr; 108(3):308-314. PubMed ID: 33608712
[TBL] [Abstract] [Full Text] [Related]
4. Galgo: a bi-objective evolutionary meta-heuristic identifies robust transcriptomic classifiers associated with patient outcome across multiple cancer types.
Guerrero-Gimenez ME; Fernandez-Muñoz JM; Lang BJ; Holton KM; Ciocca DR; Catania CA; Zoppino FCM
Bioinformatics; 2020 Dec; 36(20):5037-5044. PubMed ID: 32638009
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes.
Prabhakaran S; Rizk VT; Ma Z; Cheng CH; Berglund AE; Coppola D; Khalil F; Mulé JJ; Soliman HH
Breast Cancer Res; 2017 Jun; 19(1):71. PubMed ID: 28629479
[TBL] [Abstract] [Full Text] [Related]
6. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the pam50 risk of recurrence score and intrinsic subtype.
Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the pam50 risk of recurrence score.
Sestak I; Cuzick J; Dowsett M; Lopez-Knowles E; Filipits M; Dubsky P; Cowens JW; Ferree S; Schaper C; Fesl C; Gnant M
J Clin Oncol; 2015 Mar; 33(8):916-22. PubMed ID: 25332252
[TBL] [Abstract] [Full Text] [Related]
8. The pam50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
[TBL] [Abstract] [Full Text] [Related]
9. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the pam50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
[TBL] [Abstract] [Full Text] [Related]
